{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Chi-squared"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.2"},{"groupId":"OG001","value":"38.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"439"},{"groupId":"OG001","value":"404"}],"units":"Participants"}],"description":"The rate of prostate rebiopsy at two years is defined as the proportion of patients whose results are positive among all eligible patients who had a repeat biopsy at two years. The rate was estimated separately in each arm.","groups":[{"description":"Neoadjuvant total androgen suppression (TAS) - Flutamide and Zoladex or Lupron - two months before and during radiation therapy.","id":"OG000","title":"Hormone Therapy + Radiation Therapy"},{"description":"Radiation therapy alone","id":"OG001","title":"Radiation Therapy Alone"}],"paramType":"NUMBER","populationDescription":"All eligible patients who had a repeat biopsy at 2 years.","reportingStatus":"POSTED","timeFrame":"From registration to two years","title":"Positive Re-biopsy Rate at Two Years","type":"SECONDARY","unitOfMeasure":"percentage of participants"}